Terms and conditions

Disclaimer

This website is owned and maintained by QBiotics Group Limited (ABN 13 617 596 139) for the sole purpose of providing general information about the company. By accessing this site you acknowledge and agree to be bound, without limitation or qualification, by the following Terms and Conditions of use. If you do not agree to the Terms and Conditions of use, please do not use our website. We reserve the right to revise these Terms and Conditions, or any portion of them, at any time without notice by updating this posting.

Terms and conditions of use

No Warranty & No Liability
You assume all risks associated with the use of this website. You release and discharge QBiotics Group Limited and its affiliates, directors, officers, employees and agents from any and all liability which might arise from using this website or content contained in it, and any sites linked to it.

While QBiotics Group Limited uses reasonable efforts to ensure information on this website is accurate and up-to-date, the site is provided to you ‘as is’ without representations or warranties, express or implied, as to the accuracy or completeness of that information. QBiotics Group Limited reserves the right to alter, remove or add any of the information or features on this site at any time without notice or liability.

Neither QBiotics Group Limited, its affiliates, directors, officers, employees nor any other party involved in creating, producing or delivering this website shall be liable in any manner whatsoever for any direct, incidental, consequential, indirect or punitive losses or damages arising out of your access, use, or inability to use this website, or any errors or omissions in the content thereof. This includes loss or damage to your computer systems that may result from viruses or other defects which might be transmitted through the website.

Forward-looking Information
This website may contain forward-looking information and statements. Such information is subject to a variety of significant uncertainties, including scientific, business, economic and financial factors and therefore actual results may differ significantly from those presented or forecast.

Medical & Health Information
Any material on this site relating to disease, health or medical conditions and their treatment is provided for information purposes only. It should not be relied on and is not meant to be a substitute for advice that should be provided by a physician or other healthcare professional.

Links
This site contains links to third party web pages. These links are provided for convenience only and do not imply endorsement or approval by QBiotics Group Limited. Using these links is entirely at your own risk.

Copyright
The contents of this site are protected by copyright and owned by or licensed to QBiotics Group Limited. You may freely browse this site, but you may only access, download or use information from this site for personal, non-commercial purposes. With the exception of the foregoing limited authorization, nothing contained on the website shall be construed as granting any license or right under patent, trademark, copyright or other intellectual property right of QBiotics Group Limited. You may not distribute, modify, transmit, reproduce or use the information for commercial purposes without express written permission of QBiotics Group Limited.

FDA-CVM WARNING: SEVERE WOUND FORMATION IN HUMANS; EXTENSIVE WOUND FORMATION, MAST CELL DEGRANULATION, AND DEATH IN DOGS DUE TO MAST CELL DEGRANULATION

Human Safety

  • Accidental self-injection of STELFONTA® may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary (see Dosage and Administration, Human Warnings and Adverse Reactions).

Dog Safety

  • Always administer a corticosteroid, an H1 receptor blocking agent (e.g. diphenhydramine), and an H2 receptor blocking agent (e.g. famotidine) when treating with STELFONTA to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation (see Contraindications and Dosage and Administration).
  • Do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock (e.g. on the body, head, or neck). This may result in accumulation of necrotic debris in the subcutaneous space increasing the risk of systemic adverse reactions, including death, from mast cell degranulation (see Contraindications, Warnings and Adverse Events).
  • Treatment with STELFONTA has been associated with cellulitis and severe tissue sloughing extending away from the treated site resulting in extensive wounds that require additional treatment and prolonged recovery times (see Warnings, Precautions and Adverse Events).

IMPORTANT SAFETY INFORMATION
Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation.

Full prescribing information